FINWIRES · TerminalLIVE
FINWIRES

$A

24 stories mentioning AUpdated 4d ago

Every FINWIRES story that references A, newest first.

What are analysts saying about A?

Recent broker actions mentioned in FINWIRES coverage. Compiled from wire headlines; not investment advice.

What's the latest news on A?

Wire

Agilent Facing Product Cycle Momentum Across Key Platforms, RBC Says

Agilent Technologies (A) is facing product cycle momentum across key instrument platforms, with tailwinds from drug manufacturing exposure amid US pharmaceutical reshoring, RBC Capital Markets said in a note emailed Wednesday.The company's newly launched instruments have early commercial traction, as evidenced by the growth of its liquid chromatography and single-quad mass spectrometry, RBC said, noting that a synchronized upcycle in key platforms can be a growth driver.In addition, Agilent expects the US pharma reshoring to present a $1 billion boon for analytical instruments, the firm noted. RBC said the company has about a 25% sales exposure to this opportunity with its analytical tools used for quality control and specialty contract manufacturing services.Agilent is set to release its fiscal Q2 results after the stock market closes on Wednesday.RBC Capital Markets initiated coverage of Agilent, with an outperform rating and a $153 price target.Price: $115.50, Change: $+0.42, Percent Change: +0.36%

$A
Research

RBC Initiates Agilent Technologies at Outperform With $153 Price Target

Agilent Technologies (A) has an average rating of overweight and mean price target of $160.73, according to analysts polled by FactSet.

$A
Wire

Baird Adjusts Agilent Technologies Price Target to $156 From $155, Maintains Outperform Rating

Agilent Technologies (A) has an average rating of overweight and mean price target of $161.21, according to analysts polled by FactSet.Price: $115.35, Change: $+0.56, Percent Change: +0.49%

$A
Research

Research Alert: CFRA Moderates View On Shares Of Agilent Technologies Inc. From Buy To Hold

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We lower our 12-month price target from $140 to $120, reflecting an 18.3x P/E multiple of our unchanged FY 27 (Oct.) EPS estimate of $6.57 (FY 26 EPS estimate raised $0.01 to $5.97), a discount to Agilent's one- and three-year historical forward averages of 20.2x and 21.2x, respectively. We think headwinds may persist across key life sciences end markets due to macroeconomic pressures, uncertain tariff and research funding policy, and weaker biotech spending and clinical trial activity. Our target multiple is near recent forward valuations for key life sciences tools & services peers Danaher Corporation (DHR), Thermo Fisher Scientific Inc. (TMO), Waters Corporation (WAT), and Revvity Inc. (RVTY). The sub-industry recently traded at a roughly 25% discount to its three-year historical forward average. Agilent will report Q2 FY 26 earnings after the market close on May 27, when we anticipate 7.5%-8.0% comparable growth in both sales and EPS.

$A

Showing 21-24 of 24

Track with the FINWIRES app suite

FolioX
FolioX
Track A in your portfolio
WheelAI
WheelAI
Analyze A options with the wheel strategy
StockInsider
StockInsider
See market sentiment on A